Compare RBA & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBA | NBIX |
|---|---|---|
| Founded | 1958 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0B | 14.4B |
| IPO Year | 1998 | 1996 |
| Metric | RBA | NBIX |
|---|---|---|
| Price | $103.96 | $152.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 20 |
| Target Price | $122.00 | ★ $175.10 |
| AVG Volume (30 Days) | ★ 935.5K | 923.0K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ 14.05 | 12.44 |
| EPS | 2.10 | ★ 4.19 |
| Revenue | ★ $4,528,900,000.00 | $2,682,700,000.00 |
| Revenue This Year | $6.20 | $23.76 |
| Revenue Next Year | $4.20 | $18.01 |
| P/E Ratio | $49.51 | ★ $36.44 |
| Revenue Growth | 8.26 | ★ 19.61 |
| 52 Week Low | $86.68 | $84.23 |
| 52 Week High | $119.58 | $160.18 |
| Indicator | RBA | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 62.60 | 57.42 |
| Support Level | $98.84 | $151.59 |
| Resistance Level | $100.47 | $156.70 |
| Average True Range (ATR) | 1.77 | 4.18 |
| MACD | 0.97 | 0.35 |
| Stochastic Oscillator | 83.95 | 64.51 |
RB Global has evolved into a leading global marketplace that connects buyers and sellers of commercial assets and vehicles. It is the result of the 2023 combination of Ritchie Bros. and IAA. Ritchie Bros.' roots were as an auctioneer facilitating transactions of commercial, construction, and transportation equipment (excavators, bulldozers, forklifts, and commercial trucks and trailers). However, it has evolved into an omnichannel marketplace. IAA has similar roots, though primarily focused on the salvage auction segment for consumer automobiles. The group provides ancillary services including title processing, transportation/towing, financing, data and appraisal, and so on. Its activities are international, though skewing approximately two-thirds to North America.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.